Copanlisib (BAY 80-6946) is a potent, selective and ATP-competitive pan-class I PI3K inhibitor, with IC 50 s of 0.5 nM, 0.7 nM, 3.7 nM and 6.4 nM for PI3Kα , PI3Kδ , PI3Kβ and PI3Kγ , respectively. Copanlisib has more than 2,000-fold selectivity against other lipid and protein kinases, except for mTOR . Copanlisib has superior antitumor activity.
Products | Products > Signaling Pathways > PI3K/Akt/mTOR | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Signaling Pathways > PI3K | Products > Signaling Pathways > Apoptosis
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.